Sepracor reduces stake in BioSphere Medical:
This article was originally published in Clinica
Executive Summary
BioSphere Medical, a Nasdaq-quoted US company which is developing embolotherapy and non-embolotherapy applications for its proprietary bioengineered acrylic beads, is to offer four million shares at $11 a share. Two million come from pharmaceuticals manufacturer Sepracor, which presently owns more than 50% of BioSphere. Sepracor has seen its own share price fall from $138.25 to less than $38 in the past 52 weeks.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.